PRINCETON, N.J., and PARIS, STENTYS S.A.  a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it has joined the Stent for Life (SFL) Initiative as a key industry partner.

The Stent for Life Initiative is a unique European platform for interventional cardiologists, government representatives, industry partners, patient groups and patients to work together and, by helping to shape health care systems and medical practices, ensure that the majority of patients with acute heart attack have equal access to the life-saving indication of percutaneous coronary intervention (PCI) and stenting. The Initiative has been rolled out in 10 countries to date.

“There is irrefutable scientific evidence that revascularization with coronary stents in patients with acute myocardial infarction is life-saving: it not only reduces mortality but also reduces rates of non-fatal reinfarction when compared to the previous standard of care— pharmacological treatment,” said Gonzague Issenmann, CEO and co-founder of STENTYS. “We are extremely proud to contribute to the Stent for Life mission to increase patient access to this therapy.”

STENTYS recently announced that it has reached the mid-point of its international APPOSITION III study of its Self-Apposing Stent, with 250 patients now enrolled out of a total of 500. The trial primary endpoint is Major Adverse Cardiac Events (MACE) at 12 months post-procedure.

AMI affects 100,000 people each year in France and an additional 900,000 people in the United States and represents an annual worldwide market of approximately $2 billion.

Source: STENTYS